The role of small-colony variants in failure to diagnose and treat biofilm infections in orthopedics
Neut, Danielle; van der Mei, Henny C.; Bulstra, Sjoerd K.; Busscher, Henk J.

Published in:
Acta Orthopaedica

DOI:
10.1080/17453670710013843

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2007

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
The role of small-colony variants in failure to diagnose and treat biofilm infections in orthopedics

Daniëlle Neut, Henny C Van Der Mei, Sjoerd K Bulstra & Henk J Busscher

To cite this article: Daniëlle Neut, Henny C Van Der Mei, Sjoerd K Bulstra & Henk J Busscher (2007) The role of small-colony variants in failure to diagnose and treat biofilm infections in orthopedics, Acta Orthopaedica, 78:3, 299-308, DOI: 10.1080/17453670710013843

To link to this article: https://doi.org/10.1080/17453670710013843

© 2007 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted

Published online: 08 Jul 2009.

Article views: 1225

View related articles

Citing articles: 46 View citing articles
Review

The role of small-colony variants in failure to diagnose and treat biofilm infections in orthopedics

Daniëlle Neut1,2, Henny C van der Mei1, Sjoerd K Bulstra2, and Henk J Busscher1

Departments of 1Biomedical Engineering and 2Orthopaedic Surgery, University Medical Center Groningen, and University of Groningen, Groningen, the Netherlands
Correspondence DN: d.neut@med.umcg.nl
Submitted 06-07-19. Accepted 06-10-30

ABSTRACT Biomaterial-related infection of joint replacements is the second most common cause of implant failure, with serious consequences. Chronically infected replacements cannot be treated without removal of the implant, as the biofilm mode of growth protects the bacteria against antibiotics. This review discusses biofilm formation on joint replacements and the important clinical phenomenon of small-colony variants (SCVs). These slow-growing phenotypic variants often remain undetected or are misdiagnosed using hospital microbiological analyses due to their unusual morphological appearance and biochemical reactions. In addition, SCVs make the infection difficult to eradicate. They often lead to recurrence since they respond poorly to standard antibiotic treatment and can sometimes survive intracellularly.

Most studies on the interaction of the prosthesis with infecting organisms have shown that bacteria readily attach to devices during implantation (Lidwell et al. 1983). The main sources of contamination are the patient’s skin and airborne particles from theater personnel (Pittet and Ducel 1994). The adhesion of bacteria itself is a complicated process. All biomaterials undergo changes at the surface after implantation. The earliest and probably clinically most important step is the “race for the surface”, a contest between tissue cell integration and bacterial adhesion to that same surface (Gristina 1987). On contact, body fluids immediately coat all surfaces with a layer of host material, mainly plasma proteins and platelets. These host proteins promote attachment of bacteria onto the implant by specific receptors and by non-specific mechanisms that may depend on their chemical composition, their hydrophobicity, and the charge of the implant surface (Bos et al. 1999). After their adhesion, the bacteria encase themselves in a hydrated matrix of polysaccharides and proteins (Costerton et al. 1999) to form a slimy layer known as a biofilm (Figure 1).

Bacteria within this protective biofilm can remain “dormant” on the surface of a prosthesis for a long time; however, when the environmental circumstances change—such as reduced host immune function—biofilm bacteria can cause a clinical
infection. Generally speaking, biofilm infections will not clear until the implant has been removed and the patient must then be given antibiotic therapy. This treatment can prolong the patient’s stay in hospital by several weeks, and additional surgery may be required. Infection is thus a devastating complication from the point of view of both the patient and society, as it is associated with a substantial increase in morbidity and adds significant costs to the healthcare system.

The infection rate from joint replacements has dropped dramatically since the procedure was first performed in the late 1960s, but even so about 1% of all patients develop such an infection (Josefsson and Kolmert 1993, Philips and Crane 2006). This percentage may seem small, but since these joint replacement operations are so common, it is a complication that affects a significant number of patients. Moreover, biofilm infections can cause severe problems, ranging from disfunctioning of the implanted device to lethal sepsis. Furthermore, treatment of biofilm infections is complicated, as biofilms offer enhanced protection for the infecting organisms against the natural host defenses and antibiotic therapy (Gristina and Costerton 1985). Bacteria in a biofilm are able to resist higher antibiotic concentrations than planktonic bacteria. In general, bacteria in a biofilm are 10–1,000 times more resistant to antibiotics than their planktonic counterparts (Widmer 2001, Mah et al. 2003). Also, some bacteria (such as *Staphylococcus aureus*) form small-colony variants, characterized by reduced growth rate, resistance to aminoglycosides, and possible intracellular persistence (Proctor and Peters 1998).

In this review we first summarize current knowledge regarding the formation of an infectious biofilm on orthopedic implants, and the mechanisms used by infectious organisms to cause a deep and chronic infection. We pay special attention to the role of strains resulting from a modification of bacterial phenotype, so-called small-colony variants (SCVs), in biofilms. Finally we review the failures in diagnosis and treatment in orthopedic surgery caused by SCVs, including possible clinical consequences.

**Small-colony variants (SCVs)**

The pathogenesis of many orthopedic infections is related to the presence of microorganisms in biofilms. Bacteria that attach to a surface and grow as a biofilm are protected from the killing action of antibiotics. The protective mechanisms at work in biofilms appear to be distinct from those that are responsible for conventional antibiotic resistance (Gracia et al. 1997, Sheldon 2005). The biofilm can act as a shield for the bacteria, making it difficult for them to be reached and destroyed by antibiotic drugs. Two main mechanisms have been proposed to explain how bacteria in biofilms become resistant: (1) antibiotics do not reach bacteria present in the deeper layers of biofilms because of the difficulty in penetrating the exopolysaccharide gel (slime), and (2) bacteria in deeper layers may be in a metabolic state that makes them less susceptible to antibiotics (Costerton et al. 1987). Arciola et al. (2005) found that exopolysaccharide-producing bacterial strains showed a significantly higher occurrence of antibiotic resistance than those strains that did not produce exopolysaccharides. This may explain why only one-third of prosthetic joint infections caused by slime-positive organisms can be successfully treated with antibiotics, while all infections caused by slime-negative organisms can be cured by antibiotic therapy (Davenport et al. 1986).

Although bacteria in biofilms are surrounded by an exopolysaccharide matrix that can restrict the
diffusion of antibiotics, this may not be the central reason for biofilm-related antibiotic resistance. Jefferson et al. (2005) showed that the antibiotic vancomycin can fully penetrate the biofilm but the diffusion rate in a biofilm is significantly reduced as compared to in water. This suggests that whereas planktonic bacteria are quickly exposed to a high concentration of antibiotics, bacteria in the deeper layers of the biofilm are exposed to a gradually increasing antibiotic concentration. Darouiche et al. (1994) showed good penetration of biofilms by vancomycin, but that the resident bacteria were resistant. Likewise, rifampin has been found to penetrate biofilms formed by Staphylococcus epidermidis but fails to kill the bacteria effectively (Zheng and Stewart 2002). These studies indicate that even though the biofilm is not a physical barrier, it somehow does cause antibiotic resistance.

Based on their own results, Ashby et al. (1994) suggested that the growth rate of the bacteria in biofilms plays a role in antibiotic resistance. The bacteria in a biofilm do not grow exponentially; they are influenced by high cell densities (Fux et al. 2005) and are in a slow-growing or stationary phase (Costerton et al. 1999, Fux et al. 2005). However, not all biofilm bacteria are resistant to antibiotics; most cells die after antibiotic therapy and only a small proportion of bacteria usually survive (Ashby et al. 1994, Muli and Struthers 1998). It has been suggested that some bacterial cells in the biofilm develop a phenotype that renders them resistant to antibiotics (Cochran et al. 2000, Lewis 2005) and that this development is triggered by environmental signals. The resistant cells are called persister cells (Stewart 2002, Lewis 2005).

Biofilm bacteria may produce persister cells that neither grow nor die in the presence of antibiotics (Cogan 2006). Persister cells are largely responsible for the high levels of tolerance to antibiotics seen in biofilms (Lewis 2005), but the environmental stimuli that turn on the switch to the persister phenotype are poorly understood. Keren et al. (2004) stated that production of Escherichia coli persisters depends on the phase of growth, since maintaining the E. coli culture at early exponential phase eliminated the persister cells. Similar dynamics were observed with Pseudomonas aeruginosa and S. aureus (Keren et al. 2004). Using a mathematical model of biofilm dynamics, Roberts and Stewart (2005) predicted that the number of persister cells increases in the biofilm despite the fact that they are unable to grow, with accumulation in regions of nutrient and oxygen depletion. In these regions, although normal cells are unable to grow, they slowly switch to the persister phenotype. Cogan (2006) suggested that expression of persister cells is controlled by the growth rate and the antibiotic concentration. Persister cells can be regarded as specialized survivor cells. After the antibiotic treatment has stopped, surviving persister cells are able to revert quickly to normal cells, thus allowing the biofilm to grow again (Roberts and Stewart 2005).

The clinical impact of an infection depends on the capacity of the infecting organisms to form a biofilm and the ability of bacterial subpopulations to switch to the dormant metabolic state known as small-colony variants (SCVs). Although it is not known whether SCVs and persister cells express exactly the same set of genes, there are many similarities between SCVs and persister cells, especially regarding how both subpopulations are formed and their reduced sensitivity to antibiotics. Bayston (2000) hypothesized that the formation of SCVs takes place when the biofilm is thick enough to serve as a barrier for oxygen and nutrients. Nutrient and oxygen limitation causes some bacteria in the lower layers of the biofilm to enter a non-growing or “dormant” state: the SCVs, in which they are less susceptible to growth-dependent antibiotic killing.

Many infections in the developed world are caused by biofilms, which has sparked renewed interest in SCVs. The clinical relevance of SCVs has been unclear for a long time. Many recent studies have shown that SCVs are largely responsible for the recalcitrance of infections caused by biofilms (von Eiff et al. 1997, 1999, Drenkard and Ausubel 2002, Seifert et al. 2003). The significance of SCVs as causative organisms in chronic and recurrent infections has been demonstrated in patients with chronic osteomyelitis (von Eiff et al. 1997) and cystic fibrosis (Haussler et al. 1999, Drenkard and Ausubel 2002, Kiristis et al. 2005). In the treatment of chronic osteomyelitis with gentamicin-loaded bone cement beads, the slow release of gentamicin from the beads into the local environment is an efficient way of selecting for
SCVs (von Eiff et al. 1997). In a study of *S. aureus* strains isolated from patients with osteomyelitis, SCVs were found in about 29% of the cases (von Eiff et al. 1997). Likewise, the occurrence of *S. aureus* SCVs is observed in patients with cystic fibrosis (CF) after long-term antibiotic treatment (Kahl et al. 2003a). Analysis of sputum from CF patients showed that more than two-thirds were chronically colonized by *S. aureus*, and half of these samples were found to contain SCVs (Kahl et al. 2003b). Also, *P. aeruginosa* appears to play a role in the CF lung and *P. aeruginosa* SCVs were isolated from one-third of NN patients with *P. aeruginosa* infected lungs (Haussler et al. 1999). Recently, implant-related infections due to SCVs have been described, involving pacemakers (Seifert et al. 2003), ventriculoperitoneal shunts (Spanu et al. 2005), and hip replacements (Sendi et al. 2006).

**Characteristic features of SCVs**

The phenomenon of SCVs has been reported for several genera and species of bacteria, including the genera *Staphylococcus* (Figure 2) and *Pseudomonas*, and diverse species of Enterobacteriaceae (Bayer et al. 1987, Wise 1998, Costerton et al. 1999). Most SCVs isolated from clinical specimens have been identified as *S. aureus*. SCVs share many characteristic features, but since the greatest amount of information available relates to *S. aureus*, we have concentrated on *S. aureus* SCVs in this review.

SCVs of *S. aureus* (Table) grow slowly and produce small colonies on standard media. These are 10 times smaller than the usual *S. aureus* colonies (Bergoge-Berezin 2000). SCVs have the ability to revert to normal growth (Musher et al. 1977, Lewis et al. 1991) but there are no data available about the genetic events responsible for the reappearance of larger colonies. In addition, *S. aureus* SCVs are characterized as electron transport-deficient bacteria because of their auxotrophism to hemin.
or menadione. Hemin/menadione auxotrophy is the inability of an organism to synthesize hemin or menadione, which is required for its growth. Hemin or menadione auxotrophs will therefore only be able to grow if hemin or menadione can be taken up from the environment. Consequently, these SCVs produce very small, mostly non-pigmented, and non-hemolytic colonies on normal agar plates. Moreover, they show various other features that are atypical of *S. aureus*, including reduced coagulase production and increased resistance to aminoglycosides and cell wall-active antibiotics (von Eiff et al. 1997, Proctor and Peters 1998, Proctor et al. 1998, Kahl et al. 1998, 2003a, Seifert et al. 1999, Baumert et al. 2002). Furthermore, the ability of these variants to persist intracellularly within non-professional phagocytes, cells other than macrophages and neutrophils, has been described (Kahl et al. 1998, von Eiff et al. 2001, Vaudaux et al. 2002). *S. aureus* SCVs are capable of living intracellularly and consequently survive antibiotic therapy because they produce reduced levels of α-toxin, which prevents the cells from lysing (von Eiff et al. 2000).

**Auxotrophism**

Intraoperative specimens provide the most accurate samples for microbiological culture and are frequently used as the reference standard for diagnosing infected joint replacements. However, standard microbiological culture techniques are only moderately sensitive and specific in diagnosing infected arthroplasties. A very low inoculum, adherent bacteria, and the existence of SCVs may limit detection. Consequently, a significant proportion of these infections is probably never recognized (Philips and Kattapuram 1983, Tunney et al. 1998, Costerton et al. 1999, Neut et al. 2003). The incidence of infection in joint prostheses may therefore be grossly underestimated, and hypothetically it might be argued that inadequate microbial sampling by current hospital diagnostic methods is at least partially responsible for the high failure rates in revision surgery. Adequate sampling is extremely important in clinical practice—as, for example, septic joint prostheses require eradication of the infecting bacteria before implantation of a new prosthesis, whereas uninfected joint prostheses can be replaced immediately.

Although microscopic morphology and cell size, and Gram staining of SCVs may be normal (Haussler et al. 1999, Looney 2000), clinical microbiology laboratories may fail to detect them. Since these phenotypic variants have a low metabolism and grow very slowly on standard agar plates, they can easily be missed in a routine laboratory, where tissue samples are cultured for only 48 h. Colony formation by SCVs can often be detected on culture media after 48–72 h of culture during primary isolation (Proctor et al. 1995, Roggenkamp et al. 1998). Neut et al. (2003) showed that prolonging the culture period of microbiological samples from infected joint prostheses could double the detection
rate for infections, as bacteria in biofilms generally require a longer time in culture (Atkins and Bowler 1998). As *S. aureus* SCVs show generation times of up to 6 times longer than that for metabolically normal *S. aureus* (Proctor et al. 1995), cultures for detection of SCVs should be incubated for at least 6 days (Looney 2000). The addition of hemin and menadione to routine blood agar used for hospital culture increases the detection rate, as SCVs form normal-sized colonies and grow at the same speed as the parent strain on agar plates enriched with hemin and menadione (Kahl et al. 2003a). SCVs cultured from patients with persistent and relapsing infections have been shown to be auxotrophic for hemin and/or menadione (Proctor and Peters 1998). Supplementation of the auxotrophs with exogenous menadione or hemin resulted in normal growth and morphology, and increased hemolytic activity (Balwit et al. 1994). Subcultivation of SCVs showed hemin-dependent growth: formation of larger colonies (diameter 2 mm) in the presence of hemin and formation of small colonies (diameter 0.2 mm) in its absence (Roggenkamp et al. 1998).

Because of their particular growth characteristics, atypical morphological appearance, and unusual biochemical reactions (e.g. reduced toxin production), SCVs present a challenge to the clinical microbiologist, often resulting in misidentification (Proctor and Peters 1998). For example, Seifert et al. (2003) described case studies in which blood cultures yielded non-pigmented and non-hemolytic staphylococci, which were initially identified as coagulase-negative staphylococci on the basis of a negative tube coagulation test and the API ID 32 Staph system. However, the morphological appearance of colonies was suggestive of SCVs of *S. aureus*, and this was confirmed by DNA amplification using the polymerase chain reaction (PCR). Likewise, using molecular methods, Spanu et al. (2005) identified *S. aureus* SCVs that were methicillin-resistant, while these had originally been identified by 3 widely used automated identification systems as being methicillin-susceptible coagulase-negative staphylococci. Thus, it is most important to take SCVs into account as a possible cause of persistent infectious diseases, particularly when no bacteria or unusual microorganisms can be found in specimens from such cases.

**Reduced production of virulence factors**

When there is a suspicion of an infected joint prosthesis, biochemical investigations can be performed. Erythrocyte sediment rate (ESR) and C-reactive protein (CRP) levels are important laboratory parameters in the diagnosis of postoperative infection in patients. In joint prosthesis infections caused by bacteria of high virulence, high CRP and ESR values are common (Shih et al. 1987, Sanzén and Carlsson 1989), but in low-grade infections the absence of elevated levels of these two parameters does not exclude the possibility of a biofilm infection. Most recent studies tend to favor CRP over ESR, mainly because of the fact that ESR is affected by a multitude of factors (Ng 1998). CRP levels rise early and before the onset of clinical symptoms, and decline with the resolution of infection. Cytokines, particularly IL-6, induce synthesis of CRP in the liver (Kragsbjerg and Holmberg 1995). As part of their general reduction in metabolic activity, *S. aureus* SCVs do not produce virulence factors such as α-toxin, coagulase, or other products that are associated with stimulation of cytokine release and immune response (Bayston 2000). Limited release of cytokines at the site of an infection with SCVs does not cause elevated levels of CRP. Thus, measurement of the CRP level is not an adequate diagnostic tool when establishing that there is a postoperative infection caused by SCVs.

**Failure in treatment of biofilm infections in orthopedics**

Treatment of infected joint replacements is difficult, and usually requires appropriate surgical intervention combined with a prolonged course of antibiotic therapy. The choice of optimal management depends on the duration and pathogenesis of the infection, stability of the implant, antibiotic susceptibility of the pathogen, and condition of the soft tissue. To eradicate chronic prosthesis infection, most authors recommend removal of the implant (McDonald et al. 1989, Tattevin et al. 1999) and two-stage revision surgery. Prior to a successful reimplantation after infection, the infection should be fully eradicated through surgical debridement and removal of the prosthesis. Subsequently, high local levels of antibiotics can be achieved in the compromised tissue by implantation of chains of gentamicin-loaded bone cement beads, before a
second prosthesis is actually implanted. The gentamicin concentration that can be achieved in this way is much higher than with systemic administration (Walenkamp 1997). These beads are usually removed after 2 weeks and the absence of cultivable microorganisms in excised soft tissue samples by routine hospital culture is taken as a sign that the infection has been eradicated, and implantation of a new prosthesis can take place. Although the use of gentamicin-loaded beads is accepted in clinical practice, the beads themselves can act as a biomaterial surface to which subpopulations of bacteria may preferentially adhere, grow and possibly even develop antibiotic resistance (Neut et al. 2001).

The slow release of gentamicin from the beads into the local environment is an efficient way of selecting for SCVs (von Eiff et al. 1997). In routine hospital culture, such minority populations are disregarded, but their presence may have consequences in the subsequent treatment of a patient after orthopedic revision surgery. Neglecting SCVs will contribute to the occurrence of reinfections after employing gentamicin-loaded beads, and this may be one of the reasons for higher infection rates after revision surgery.

**Antibiotic resistance**

Bacteria persisting as SCVs within biofilms may explain the recurrent nature of biofilm infections. SCVs cause persistent and relapsing infections due to their increased resistance to antibiotics. The depressed electron transport activity seen in these auxotrophic SCVs may account for their in vitro resistance to a variety of antibiotics (Proctor and Peters 1998). In addition, SCVs have defective catalase activity, which may interfere with oxidative metabolism and aminoglycoside uptake (Rusthoven et al. 1979). The low content of ATP in SCVs causes inefficient transport of aminoglycosides into the cell, resulting in increased resistance to gentamicin and other aminoglycosides (Proctor and Peters 1998). The minimum inhibitory concentrations of four aminoglycoside antibiotics were found to be 8- to over 16 times higher for SCVs than for the normal large colony type (Rusthoven et al. 1979). Moreover, the slow growth of SCVs and consequently cell-wall division reduces the effectiveness of antibiotics that act at the cell wall (Looney 2000). However, SCVs are susceptible to a range of antibiotics with other modes of action, the hydrophilic antibiotics tetracycline and erythromycin for example, and to the hydrophobic antibiotics rifampicin and chloramphenicol (Langford et al. 1989). For optimal eradication of SCVs, treatment should consist of therapy with an antibiotic that has optimal bactericidal activity against slowly growing bacteria (Vaudaux et al. 2006). Rifampin may be the most efficient antibiotic because of its excellent efficacy against stationary and adherent bacteria (Widmer et al. 1990). Although rifampin has very good bactericidal activity against slow-growing bacteria, it should be given in combination with other antibiotics because of the rapid emergence of resistance when given alone (Vaudaux et al. 2006). The combination proposed by Sendi et al. (2006), rifampin with a fluoroquinolone, has been shown to be successful when dealing with hip replacements infected with S. aureus SCVs.

**Intracellular survival**

*S. aureus* SCVs can survive inside non-professional phagocytes, such as endothelial cells and osteoblasts (Hudson et al. 1995, von Eiff et al. 2000). These SCVs have a dampened production of cytotoxins and this may downregulate the induction of cell lysis or apoptosis (Proctor et al. 2006). Unlike the wild type, they do not kill the cells because they produce very little α-toxin (von Eiff et al. 2000). Their reduced virulence creates a completely new niche for these bacteria inside the host cell (Proctor 1994, Proctor et al. 1995). The intracellular location may shield these SCVs from the host defenses and exposure to antibiotics (Kahl et al. 1998, Vaudaux et al. 2002, von Eiff et al. 2001), thus providing one explanation for the difficulty in clearing SCVs from host tissues. In addition, *S. aureus* SCVs can also be phagocytosed by monocytes and macrophages. They can hide within these host cells, then revert to the highly virulent rapidly growing form and lyse the host cell once the host immune response has dropped and antibiotic therapy is complete (von Eiff et al. 2000). *S. aureus* persisting as SCVs inside host cells may also be an explanation for the recurrent nature of these biofilm infections.

**Conclusions**

Clinical and laboratory findings lead to the con-
conclusion that SCVs must be actively sought after in clinical microbiology, because they grow very slowly and can easily be missed. Particularly those samples from patients who have undergone long-term antibiotic therapy (e.g. antibiotic-loaded bone cement beads or spacers) or from individuals suffering from unusually persistent or recurrent infections should be examined meticulously for SCVs. In addition, it is most important to take SCVs into account as a possible cause of persistent infectious diseases when no bacteria or unusual microorganisms are found in materials obtained from such cases. Also, due to reduced production of virulence factors by SCVs, absence of elevated levels of CRP in patients postoperatively does not exclude the possibility of a biofilm infection. An optimal treatment of SCV-mediated infections has not been established, but these bacterial forms show increased resistance to aminoglycosides and cell-wall active antibiotics.

**Contributions of authors**

DN: conception and design of the study, data collection, analysis, and manuscript preparation. HvDM, SB, and HB: study design, analysis, and revision of the manuscript.

No competing interests declared.


Roberts M E, Stewart P S. Modelling protection from antimicrobial agents in biofilms through the formation of persister cells. Microbiology 2005; 151: 75-80.


